Jain PharmaBiotech, May 2012, Pages: 633
known to have a neuroprotective effect. With the approval of new products and takeover of markets for obsolete symptomatic therapies, the neuroprotection market value will rise by the year 2016 when it
Life Science Intelligence, Inc., Jan 2012, Pages: 101
- Ready-to-market medical device for assessing - via the eye - exposure to neurotoxins, cyanide, and low level radiation. Future products include assessment of mild TBI and other health conditions
Life Science Intelligence, Inc., Jan 2011
monitoring device
- Advanced, portable and easy-to-use noninvasive devices for the assessment of traumatic brain injury (TBI) at the point of care
- Interventional cardiology devices for chronic total
Jain PharmaBiotech, May 2012, Pages: 1037
technologies, applications and geographical regions. Forecasts are made up to 2021. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and
Life Science Intelligence, Inc., Dec 2009, Pages: 1763
with high bioavailability
- Monitoring system to replace the manual assessment of labor progress with real-time/continuous information
- Device for the treatment of Barrett's esophagus and prevention
Life Science Intelligence, Inc., July 2007
delivery of biological therapeuticsto the nervous system
Company 74 - Disposable balloon cervical dilator for improved uterine access that decreases pain, avoids tearing and perforations
Company 75 - First
